Literature DB >> 12003708

Functional tests for primary aldosteronism: value of captopril suppression.

Marie-Claude Racine1, Pierre Douville, Marcel Lebel.   

Abstract

With the introduction of more simple screening tests such as the aldosterone/renin ratio, the detection rate of primary aldosteronism has increased considerably. Until now, no reference values have been available for reporting the aldosterone/renin ratio using plasma aldosterone values expressed in SI units (pmol/L) and plasma active renin (ng/L) measured by immunoradiometric assay. We studied 153 subjects who had either normal blood pressure, essential hypertension, or primary aldosteronism. Essential hypertensive patients usually have aldosterone/renin (pmol/L/ng/L) ratios below 100, whereas ratios for patients with primary aldosteronism are above 140. Results that fall between 100 and 140 suggest a need for repeat testing. Patients with elevated aldosterone/renin ratios require confirmatory testing to demonstrate nonsuppressive autonomous aldosterone production. To this end, salt loading is widely used, but this approach may be contraindicated in patients with severe hypertension. The captopril suppression test appears as effective as salt loading in confirming a diagnosis of primary aldosteronism. In addition, the captopril test is safe, well tolerated, and cost-effective.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12003708     DOI: 10.1007/s11906-002-0014-5

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  27 in total

1.  Improved immunoradiometric assay for plasma renin.

Authors:  J Deinum; F H Derkx; M A Schalekamp
Journal:  Clin Chem       Date:  1999-06       Impact factor: 8.327

Review 2.  Primary aldosteronism. Diagnostic evaluation.

Authors:  W F Young; G G Klee
Journal:  Endocrinol Metab Clin North Am       Date:  1988-06       Impact factor: 4.741

3.  Saline suppression of plasma aldosterone in hypertension.

Authors:  D C Kem; M H Weinberger; D M Mayes; C A Nugent
Journal:  Arch Intern Med       Date:  1971-09

Review 4.  Primary aldosteronism: A common and curable form of hypertension.

Authors:  W F Young
Journal:  Cardiol Rev       Date:  1999 Jul-Aug       Impact factor: 2.644

5.  Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology.

Authors:  C E Fardella; L Mosso; C Gómez-Sánchez; P Cortés; J Soto; L Gómez; M Pinto; A Huete; E Oestreicher; A Foradori; J Montero
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

6.  Primary aldosteronism: adrenal venous sampling.

Authors:  W F Young; A W Stanson; C S Grant; G B Thompson; J A van Heerden
Journal:  Surgery       Date:  1996-12       Impact factor: 3.982

7.  Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism.

Authors:  M Stowasser; R D Gordon; T J Tunny; S A Klemm; W L Finn; A L Krek
Journal:  Clin Exp Pharmacol Physiol       Date:  1992-05       Impact factor: 2.557

8.  Primary aldosteronism due to unilateral adrenal hyperplasia.

Authors:  A Ganguly; P G Zager; J A Luetscher
Journal:  J Clin Endocrinol Metab       Date:  1980-11       Impact factor: 5.958

9.  Isolated clinical syndrome of primary aldosteronism in four patients with adrenocortical carcinoma.

Authors:  D Farge; G Chatellier; J Y Pagny; X Jeunemaitre; P F Plouin; P Corvol
Journal:  Am J Med       Date:  1987-10       Impact factor: 4.965

10.  Angiotensin II effect on plasma steroids in selective hypoaldosteronism.

Authors:  M Lebel; J H Grose
Journal:  Horm Metab Res       Date:  1982-08       Impact factor: 2.936

View more
  2 in total

Review 1.  Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Authors:  Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-18       Impact factor: 3.872

2.  Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism.

Authors:  François Corbin; Pierre Douville; Marcel Lebel
Journal:  Int J Nephrol Renovasc Dis       Date:  2011-07-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.